Breast cancer index identifies early-stage estrogen receptor-positive breast cancer patients at risk for early- and late-distant recurrence.
about
Genomic profiling in luminal breast cancerHormonal Modulation of Breast Cancer Gene Expression: Implications for Intrinsic Subtyping in Premenopausal WomenUse of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice GuidelineTailoring therapies--improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015Meta-analytic support vector machine for integrating multiple omics data.Selecting postoperative adjuvant systemic therapy for early stage breast cancer: A critical assessment of commercially available gene expression assays.Translating RNA sequencing into clinical diagnostics: opportunities and challenges.Markers for the identification of late breast cancer recurrence.p53 accumulation is a strong predictor of recurrence in estrogen receptor-positive breast cancer patients treated with aromatase inhibitors.Epsin Family Member 3 and Ribosome-Related Genes Are Associated with Late Metastasis in Estrogen Receptor-Positive Breast Cancer and Long-Term Survival in Non-Small Cell Lung Cancer Using a Genome-Wide Identification and Validation StrategyProspective assessment of the decision-making impact of the Breast Cancer Index in recommending extended adjuvant endocrine therapy for patients with early-stage ER-positive breast cancer.Assessment of the prognostic and predictive utility of the Breast Cancer Index (BCI): an NCIC CTG MA.14 studyIdentification and prioritization of candidate genes for symptom variability in breast cancer survivors based on disease characteristics at the cellular level.Factors that predict recurrence later than 5 years after initial treatment in operable breast cancer.Prediction of late distant recurrence in patients with oestrogen-receptor-positive breast cancer: a prospective comparison of the breast-cancer index (BCI) assay, 21-gene recurrence score, and IHC4 in the TransATAC study population.How do I recommend extended adjuvant hormonal therapy?Multi-gene classifiers for prediction of recurrence in breast cancer patients.Indications for prognostic gene expression profiling in early breast cancer.The UZ Leuven Policy for Extended Adjuvant Anti-estrogen Therapy in Women With Early Estrogen Receptor-Positive Breast Cancer.Extended Adjuvant Endocrine Therapy in Breast Cancer: Evidence and Update - A Review.Weighted K-means support vector machine for cancer prediction.MetaKTSP: a meta-analytic top scoring pair method for robust cross-study validation of omics prediction analysis.Risk stratification with Breast Cancer Index for late distant recurrence in patients with clinically low-risk (T1N0) estrogen receptor-positive breast cancer.ER-positive breast cancer patients with more than three positive nodes or grade 3 tumors are at high risk of late recurrence after 5-year adjuvant endocrine therapy.Breast cancer genomics from microarrays to massively parallel sequencing: paradigms and new insights.Use of 21-gene recurrence score assay to individualize adjuvant chemotherapy recommendations in ER+/HER2- node positive breast cancer-A National Cancer Database study.Developing a new generation of breast cancer clinical gene expression testsAn unmet need: tailoring extended adjuvant endocrine therapy.Prognostic value of PAM50 and risk of recurrence score in patients with early-stage breast cancer with long-term follow-up.Endocrine Therapy for Early Breast Cancer: Updated Review.Utility of molecular tools for extended adjuvant endocrine therapy decisions in early breast cancer.Endocrine therapy and related issues in hormone receptor-positive early breast cancer: a roundtable discussion by the breast cancer therapy expert group (BCTEG).Extended Adjuvant Aromatase Inhibitor Therapy in Post-Menopausal Women.Comparison of the Performance of 6 Prognostic Signatures for Estrogen Receptor-Positive Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial.Searching for the IDEAL Duration of Adjuvant Endocrine Therapy.Understanding Biomarkers in Early-Stage Invasive Breast Cancer: Tools From the ASCO Clinical Guideline.Prognostic & predictive factors for planning adjuvant chemotherapy of early-stage breast cancer.Practical consensus recommendations on management of HR + ve early breast cancer with specific reference to genomic profiling.Addressing the challenges of applying precision oncology.An Update on Breast Cancer Multigene Prognostic Tests-Emergent Clinical Biomarkers
P2860
Q26862681-81583547-9DEA-429C-8720-4683062D5E9EQ28077637-B094D3B4-744E-43CF-930B-086D6A3E849FQ28079118-D1118D5D-C004-4942-9A97-F68828C5DBA1Q28085062-9488E8A4-3648-43BE-91D7-EB86C903D4AAQ31158830-4B688778-C424-48D7-92F1-36E0C19006ACQ33834198-FE9F3B55-FB1B-4429-8343-C9EAC900E845Q34519034-35FF6A51-A3B6-4769-B67A-FDD761E06642Q35018949-49326712-F615-4A13-A73B-86E0F9A822BCQ35051755-84F7E288-CBDB-47FD-9B93-7ABEF730327AQ36215006-8ADBC397-F77D-44E5-B2CD-3965B43BB785Q36322870-270B7C4F-FADA-4C88-B7CC-DB8B3F23F83DQ36428743-906E9BA6-5D57-4B1A-A1EB-FEE66270ABFFQ36684067-99AD4717-6E9E-4E42-91D2-4D5037A5F724Q37199625-FBFDA992-37EE-4204-81B2-7A6A6C11DCEDQ37570901-281E9969-341E-4B05-BDBA-7A5428D97FD7Q38171359-7A855130-37C4-429B-8496-2CE20A9A3E0FQ38362985-823FA958-F4F1-44A5-AB78-6B9564D1435EQ38451798-959773DA-750D-4414-AEFD-16EBA1981D94Q38510960-1DDB94BA-1B1C-43BB-8D64-8667C08BA1A0Q38933874-94D2C95F-6ADA-45D7-9FC6-401A665BDD12Q39501060-73765FA9-E3E8-48CC-AE66-0AA31C8CC645Q39788006-679B0090-2660-4962-A1E8-DCE8F57F973CQ41242766-16AC3565-0AE1-4F5E-AA22-239E1F6034E4Q42373183-604EA745-1A1B-4904-A288-9ACB906873DAQ42473382-E8E977B1-21A5-4167-A9D1-516D16C8B55CQ42670058-13312527-D260-49A7-BEF6-3109BCF6BCF9Q42737349-BACBAA9E-E27F-43E5-9896-AA2A9F0983C7Q42813847-E2AD9C7E-CA3F-4F0D-B547-77341697DC81Q47122813-74B85277-B193-458B-9CBE-BA0CC95FD0CFQ47161589-85BE7BDE-D4C8-4DDB-93EE-78FB6203F0ADQ47821919-9A81AA5F-855C-4CE3-86AA-1B1A8821772CQ48203476-AF121F1E-1F8A-4946-90E5-A0D858C7BA0AQ49334420-F59A1079-BE64-4695-9D42-39A765B3225BQ49951544-886D86F8-9A59-41B5-B11B-C7F456D222CEQ50042338-08D702F4-1D4E-473C-9492-BCDD4A4EBBFAQ53980821-D752B9F4-7CB5-4B98-818C-AC65B198C49AQ54495437-EA4AF26E-D09A-4C6B-AECB-CDB048AF8299Q54942720-E3BD58EB-F1D3-40C4-B732-DF9B2DE84F93Q55314165-BC1A1A98-99DC-4927-8A54-583827D6F1D8Q57106403-10D11A44-13B9-4730-A953-70A5AC52DDBA
P2860
Breast cancer index identifies early-stage estrogen receptor-positive breast cancer patients at risk for early- and late-distant recurrence.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh-hant
name
Breast cancer index identifies ...... - and late-distant recurrence.
@en
Breast cancer index identifies ...... - and late-distant recurrence.
@nl
type
label
Breast cancer index identifies ...... - and late-distant recurrence.
@en
Breast cancer index identifies ...... - and late-distant recurrence.
@nl
prefLabel
Breast cancer index identifies ...... - and late-distant recurrence.
@en
Breast cancer index identifies ...... - and late-distant recurrence.
@nl
P2093
P1476
Breast cancer index identifies ...... - and late-distant recurrence.
@en
P2093
Adam M Brufsky
Brock E Schroeder
Catherine A Schnabel
Dennis Sgroi
Mark G Erlander
Piiha-Lotta Jerevall
Rachel C Jankowitz
Tommy Fornander
P304
P356
10.1158/1078-0432.CCR-13-0804
P407
P577
2013-06-11T00:00:00Z